Publication Date:
2018-03-22
Description:
Key Points P4HA2, associated with progression and poor overall survival in DLBCL patients, could serve as a novel biomarker and therapeutic target. P4HA2 counteracts the negative effect of Carabin on lymphoma by hydroxylation of Carabin at Pro306.
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink